Samsrita Labs (539267)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Positive book value of ₹5.20 per share provides a tangible, if shrinking, equity base.
• Small market cap of ₹25 crore means a relatively small capital infusion or business win could move the needle.
• ROCE of -1.80% suggests operating losses are modest relative to total capital employed, leaving room for operational improvement.
• Starting from zero current sales, any genuine revenue generation would show up as significant growth from a very low base.

Concerns

• Latest quarter shows zero revenue and a net loss of ₹3 crore, so the company is currently cash-burning without proven operations.
• ROE of -70.88% indicates rapid erosion of shareholder equity and book value.
• Price-to-book of 3.29 means investors are paying a heavy premium for a loss-making business with no dividend.
• Piotroski F-score of 2/9 and insufficient data on promoter holding raise red flags about financial health and governance transparency.

AI Analysis

Dear investor, I look at Samsrita Labs and see a business that fails every test I apply. A healthcare service provider should earn meaningful returns on capital, but here ROE is -70.88% and ROCE is -1.80%. The latest quarter shows sales of zero and a net loss of ₹3 crore. You cannot value a company with no revenue and falling profitability; the trailing P/E is meaningless, and the stated P/B of 3.29 means the market prices this at ₹17.13 against book value of ₹5.20. That is a rich premium for a company destroying roughly 71% of equity each year. There is no dividend to compensate, no sales growth to project, and the Piotroski F-score of 2/9 tells me the underlying financials are weak. I am not comforted by the 52-week range of ₹13.78 to ₹25.27, as a fallen price is not by itself cheap. With FairStock score unavailable due to insufficient data, this is close to a zero-information situation. In Ben Graham's framework, the first rule is to protect your capital. Paying more than three times book for a loss-making entity with no revenue is the opposite of protection. What would change my mind? Evidence of revenue traction, a clear path to positive operating margins, better use of existing net assets, and credible promoter participation. Until then, this is not an investment; it is a speculation on a possible turnaround. I prefer businesses where the numbers already show strength, not those asking me to hope.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer